Highlights of This Issue 773

REVIEWS
775 Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment
Zihao Liu, Andrew J. Sanders, Gehao Liang, Erwei Song, Wen G. Jiang, and Chang Gong

787 Nodal Signaling as a Developmental Therapeutics Target in Oncology
Aparna Kalyan, Benedito A. Carneiro, Sunandana Chandra, Jason Kaplan, Young Kwang Chae, Maria Matsangou, Mary J.C. Hendrix, and Francis Giles

SMALL MOLECULE THERAPEUTICS
793 Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network
Suman Chatterjee, Eric H.-B. Huang, Ian Christie, Brenda F. Kurland, and Timothy F. Burns

805 Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer

819 Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
Zhanjun Hou, Leda Gattoc, Carrie O’Connor, Si Yang, Adrianne Wallace-Povilick, Christine George, Steve Orr, Lisa Polin, Kathryn White, Juwanna Kushner, Robert T. Morris, Aleem Gangjee, and Larry H. Matherly

831 Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells
Dasha E. Kenlan, Piotr Rybakhou, Vitality M. Sviripa, Heidi L. Weiss, Chunming Liu, David S. Watt, and B. Mark Evers
COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

948 Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Hatim Husain, David Nykin, Nam Bui, Daniel Quan, German Gomez, Brian Woodward, Sumathi Venkatapathy, Radha Duttagupta, Eric Fung, Scott M. Lippman, and Razelle Kurzrock

MODELS AND TECHNOLOGIES

956 Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

966 HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Karem A. Court, Hiroto Hatakeyama, Sherry Y. Wu, Mangala S. Lingegowda, Cristian Rodriguez-Aguayo, Gabriel López-Berestein, Lee Ju-Seog, Carlos Rinaldi, Eduardo J. Juan, Anil K. Sood, and Madeline Torres-Lugo

RETRACTION

977 Retraction: Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

914 Inhibition of Isoprenylcysteine Carboxymethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer
Kanjoomana Aryan Manu, Yin Fan Chai, Jing Tsong Teh, Wan Long Zhu, Patrick J. Casey, and Mei Wang

924 Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145
Guosong Jiang, Chao Huang, Jingxia Li, Haishan Huang, Honglei Jin, Junlan Zhu, Xue-Ru Wu, and Chuanshu Huang

936 Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Fumihito Noguchi, Shigeki Inui, Clare Fedele, Mark Shackleton, and Satoshi Itami

879 Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Nikolas Stefan, Rémy Gebéieux, Lorenz Waldeineier, Tamara Hell, Marie Escher, Fabian I. Wölfer, Ulf Grawunder, and Roger R. Beerli

905 Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Jörg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Beatrix Stelte-Ludwig, Carol Pena, Claudia Lange, Sven Golffer, Christoph Knep, Patricia E. Carrigan, Kirk Mclean, Kathleen Stuebner, Anthony E. Rizzardi, Jonathan C. Henriksen, Stephen Schmechel, Colleen L. Forster, Jong-Hyuk Kim, Jerry Froelich, Jillian Walz, Michael S. Henson, Matthew Breen, Kerstin Lindblad-Toh, Felix Oh, Kristy Pilbeam, Jaime F. Modiano, and Daniel A. Vallera

905 Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth

914 Inhibition of Isoprenylcysteine Carboxymethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer
Kanjoomana Aryan Manu, Yin Fan Chai, Jing Tsong Teh, Wan Long Zhu, Patrick J. Casey, and Mei Wang

924 Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145
Guosong Jiang, Chao Huang, Jingxia Li, Haishan Huang, Honglei Jin, Junlan Zhu, Xue-Ru Wu, and Chuanshu Huang

936 Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Fumihito Noguchi, Shigeki Inui, Clare Fedele, Mark Shackleton, and Satoshi Itami

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows the whole genome evaluation of copy number alterations ordered sequentially by chromosomes and represented by different colors. A patient with metastatic lung cancer was found to have very high amplification of EGFR (copy number = 15) and HFN1B (copy number = 11) detected by the cell-free DNA obtained from ascites. The results indicate that cell-free DNA from ascites and pleural effusions may provide additional data complementing tumor and plasma cell-free DNA molecular characterization, and a context for important insights into clonal dynamic change within primary tumor and metastatic deposits.
Molecular Cancer Therapeutics

16 (5)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/16/5

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/16/5.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.